Nicholas Naclerio, Director at Alamar Biosciences, Inc. (ALMR), bought 240,980 shares at $17.00 ($4.0M) on 2026-04-20, disclosed to the SEC on 2026-04-20.
Director Nicholas Naclerio purchased $3.99 million worth of shares at $17.00, marking the largest insider purchase in Alamar Biosciences' history. This significant capital commitment suggests insider confidence in the company's valuation or near-term prospects.
The stock is currently trading at $22.00, sitting 10.2% below its 52-week high of $24.50 but just 2.33% above its 52-week low of $21.50.
The company is currently evaluating its valuation following modest year-to-date gains of 4.59% as of May 14, 2026. Additionally, the largest insider purchase in the company's history occurred on April 20, 2026, signaling strong conviction from leadership.
The stock faces elevated short interest at 2.77% of the float, which could pressure the price if sentiment turns negative. Furthermore, the company's forward P/E ratio is negative at -27.67, indicating potential profitability concerns.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 5,686 | $0 | 0.0% |
| 2 | $17.00 | 235,294 | $4.0M | 100.0% |
| Total | $16.60 avg | 240,980 | $4.0M | 100% |
| Filing → |
| ILMN | SELL | 2015-06-15 | $1.4M | — | Filing → |
| ILMN | SELL | 2015-05-19 | $1.3M | — | Filing → |
| ILMN | SELL | 2015-04-16 | $1.2M | — | Filing → |